July 2024 FDA Recall Clonazepam by Endo Pharmaceuticals, Inc.
D-0622-2024 - Labeling

This Class I drug recall was voluntarily initiated by Endo Pharmaceuticals, Inc. on July 10, 2024 for the product Clonazepam. The FDA reported the reason for recall as labeling. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0622-2024

Reason for Recall
Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled as 0.125 mg instead of 0.25 mg. The blister strips inside the product carton reflect the correct strength of 0.25 mg.
Initiated
07-10-2024
Reported
08-07-2024
Quantity
8,139 cartons

Recall Profile & Regulatory Data

Class I - is a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.
Endo Pharmaceuticals, Inc.
Nationwide in the USA and Puerto Rico
Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.125mg, 60 tablets per carton (10 blister cards containing 6 tablets each), Rx Only, Distributed by: Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC# 49884-306-02.

Batch or Lot Expiration Information

Lot# Lot 550147301, Exp. 08/31/2026